Access Campaign: Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments that could save their lives
3-21 | Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).
2-24 | More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of US$1,700 per treatment course.
High vaccine prices hamper immunisation efforts in Africa, but are missing from agenda of key vaccination conference
2-23 | Ministerial Conference on Immunisation in Africa presses countries to do more, but gives free pass to pharmaceutical companies charging inflated vaccine prices.
1-19 | The conflict that erupted in South Sudan little more than a year ago has left people more vulnerable to a deadly tropical disease known as kala azar (visceral leishmaniasis). The risk of infection increases as people are displaced by fighting into areas where the disease is prevalent and malnutrition lowers their ability to fight the infection.
11-28 | With winter settling in in eastern Ukraine, Médecins Sans Frontières (MSF) is continuing its support to hospitals on both sides of the frontline, and expanding its psychological assistance to help people living in some of the hardest hit areas.